Skip to main content
. 2015 Jan 15;6(3):233–238. doi: 10.1111/1759-7714.12218

Table 5.

Second-line chemotherapy regimens (n = 102)

Regimen Cases (%)
Single agent topotecan 38 (37.3)
Combined regimen containing topotecan 16 (15.7)
EP 17 (16.7)
CE 6 (5.9)
IP 9 (8.8)
CAV 2 (1.9)
Single agent etoposide or teniposide 2 (1.9)
Other regimens 12 (11.8)

EP, etoposide with cisplatin; CAV, cyclophosphamide/adriamycin/vincristine; CE, etoposide with carboplatin; IP, irinotecan/cisplatin.